Journal of Applied Physiology, Vol 64, Issue 4 1567-1574, Copyright © 1988 by American Physiological Society

ARTICLES

Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma

C. C. Hardy, P. Bradding, C. Robinson and S. T. Holgate
Medicine 1 and Clinical Pharmacology, Southampton General Hospital, United Kingdom.

Prostacyclin (PGI2) is generated in appreciable amounts during allergic reactions in human lung tissue. To define its activity on human airways we have studied the effects of doubling concentrations of inhaled PGI2 and its hydrolysis product 6-oxoprostaglandin F1 alpha (6-oxo-PGF1 alpha) on specific airway conductance (sGaw), maximum expiratory flow at 30% vital capacity (Vmax30), forced expiratory volume in 1 s (FEV1), and static lung volumes in subjects with mild allergic asthma. In a second study the effect of inhaled PGI2 on bronchoconstriction provoked by increasing concentrations of inhaled prostaglandin (PG) D2 and methacholine was observed. Inhalation of PGI2 up to a concentration of 500 micrograms/ml had no significant effect on sGaw but produced a concentration-related decrease in FEV1 and Vmax30 in all subjects. In two of four subjects inhalation of PGI2 also increased residual volume and decreased vital capacity but had no effect on total lung capacity. PGI2, but not 6-oxo-PGF1 alpha, protected against bronchoconstriction provoked by either PGD2 or methacholine whether airway caliber was measured as sGaw, FEV1, or Vmax30. The apparent disparity between the bronchoconstrictor and antibronchoconstrictor effects of PGI2 might be explained by its potent vasodilator effect in causing airway narrowing through mucosal engorgement and reducing the spasmogenic effects of other inhaled mediators by increasing their clearance from the airways.

This article has been cited by other articles:

				G. L. Larsen, J. Loader, C. Fratelli, J.-k. B. Kang, A. Dakhama, and G. N. Colasurdo Modulation of airway responses by prostaglandins in young and fully grown rabbits Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L239 - L244. [Abstract] [Full Text] [PDF]

				J. W. Card, M. A. Carey, J. A. Bradbury, J. P. Graves, F. B. Lih, M. P. Moorman, D. L. Morgan, L. M. DeGraff, Y. Zhao, J. F. Foley, et al. Cyclooxygenase-1 Overexpression Decreases Basal Airway Responsiveness but Not Allergic Inflammation J. Immunol., October 1, 2006; 177(7): 4785 - 4793. [Abstract] [Full Text] [PDF]

				R. J. Roman P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function Physiol Rev, January 1, 2002; 82(1): 131 - 185. [Abstract] [Full Text] [PDF]

				M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs] Can J Anesth, October 1, 2001; 48(9): 924 - 929. [Abstract] [Full Text] [PDF]

				E. R. Jacobs and D. C. Zeldin The lung HETEs (and EETs) up Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H1 - H10. [Abstract] [Full Text] [PDF]

				R. A. Schroeder, G. L. Wood, J. S. Plotkin, and P. C. Kuo Intraoperative Use of Inhaled PGI2 for Acute Pulmonary Hypertension and Right Ventricular Failure Anesth. Analg., August 1, 2000; 91(2): 291 - 295. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520. [Abstract] [Full Text]